CFTR correction
Shortly after identification of the
CFTR gene, there was particular interest in and hope that insertion of a normal copy of the gene (that is, gene therapy) would restore CFTR function in persons with CF [
5]. Gene therapy has long been promised as the pathway to a cure for CF and an assumed advantage of gene therapy for CF was that the airways should present a relatively easy target to reach. However, much has been learned from gene therapy trials and the airways present many barriers to successful gene therapy, more so than many other organs. The reader is referred to a recent review of the status of CF gene therapy investigations [
48], but what has been demonstrated is that the principle of transfer of the
CFTR gene is possible and that a partial correction of the basic defect in the airways of patients with CF can be achieved without major safety issues. What has yet to be demonstrated is that
CFTR gene transfer to the lung will result in a clinical benefit and whether gene transfer and/or expression can be successfully repeated over what would be decades of treatment. The UK Cystic Fibrosis Gene Therapy Consortium is planning to initiate a multi-dose clinical trial of gene therapy in 2012, which will be the first opportunity to find out if gene therapy can result in clinical benefit.
CFTR modulation
Although we cannot currently supplement mutant
CFTR alleles with a normal copy by gene therapy, small molecules have been identified that can modulate mutant
CFTR protein such that its function may be closer to normalcy. There are more than 1,800 CF gene mutations that have been identified, but not all are known to cause disease, allowing for some patients to have minimal symptoms yet believed to have CF. For those mutations known to cause complications of CF, we categorize them based upon the major presumed defect (that is, synthesis, processing, regulation and channel conductance) [
49,
50], but these categories are not highly specific and there is considerable overlap for some mutations (that is, they could be sorted into more than one category). The general approach to evaluating CFTR-modulating drugs is to assess their ability to either increase the quantity of CFTR at the cell surface and/or increase the function of CFTR.
The first approved CFTR modulator, ivacaftor, is indicated for patients with CF with a specific mutation, G551D. This mutation results in a reduced probability of opening of the CFTR channel (an altered gating mechanism); there is a sufficient quantity of CFTR but there is impaired function of the channel [
51]. Ivacaftor potentiates the CFTR channel by increasing the probability of channel opening [
51]. A clinical trial in patients with CF with at least one copy of G551D demonstrated proof of this concept with a decrease in mean sweat chloride from approximately 100 mEq/L to approximately 51 mEq/L [
52]. More importantly, there were remarkable clinical benefits with an increase in forced expiratory volume in one second by 10.6% of predicted value, a reduction in risk of pulmonary exacerbations by 55%, an increase in weight and an improvement in quality of life [
52]. Similar results have been demonstrated in pediatric patients and ivacaftor has been approved by the Food and Drug Administration (FDA) for patients aged six years and above. There are important questions that remain to be answered, including whether the drug be used in newly diagnosed infants, will the drug work in other mutations (especially gating mutations), and will the drug have an effect on other manifestations of disease (for example, sinus disease, gastrointestinal absorption, reduction in inflammation in the airways)?
Studies that address the first question should easily be able to demonstrate an effect on sweat chloride and any new safety issues but other clinical benefits will be more challenging; is it possible that sweat chloride could serve as an acceptable surrogate clinical endpoint? As to the second question, we know that ivacaftor will not be an effective therapy alone in patients homozygous for F508del
CFTR mutations [
53]. This is not an unexpected finding as the F508del mutation results in abnormal processing of the CFTR protein such that there is a marked reduction in the quantity of CFTR at the cell surface [
54,
55]. However, it is likely that ivacaftor will potentiate F508del protein [
56], so if the quantity of F508del protein could be increased at the cell surface by a small molecule, there is the possibility that ivacaftor could be used in combination with it to increase CFTR activity. There are promising agents that may allow for correction of the CFTR processing defect seen with F508del mutations, including VX-809 [
57] and VX-661 [
58]. These are currently under investigation in combination with ivacaftor in patients with F508del mutations [
59,
60]. The last question is being addressed in an observational study of ivacaftor in patients with G551D (the GOAL study) sponsored by the Cystic Fibrosis Foundation [
61]. This provides an opportunity to understand the biology of CFTR modulation, including the direct and indirect effects of activating CFTR-dependent anion secretion by collecting specimens and clinical data on a large number of patients both before and after they begin treatment with ivacaftor.
A specific type of mutation called a nonsense (premature stop codon) mutation also results in a reduction in the quantity of CFTR protein at the cell surface. These mutations, affecting approximately 10% of patients with CF, prematurely halt translation of mRNA to protein, resulting in incomplete CFTR proteins [
62]. The strategy necessary to address this problem would require 'reading through' the mutation to the normal stop codon. Ataluren is an orally delivered investigational drug that has the potential to overcome the effects of the nonsense mutation and has been shown to induce the production of full-length functional CFTR protein at epithelial cell surfaces in mice [
63] and humans [
64]. Short-term studies of ataluren in pediatric [
64] and adult [
65] patients have shown treatment-induced improvements in CFTR-mediated chloride transport in respiratory epithelium. A Phase III clinical trial is currently under investigation in adult and pediatric patients [
66].
Alternate channels
CFTR is not the only channel on the epithelial cell surface responsible for the maintenance of the airway surface liquid. There are other chloride channels including a calcium-dependent chloride channel [
67] and the P2Y receptor activated by ATP [
68]. Early studies of uridine-5 triphosphate, an analog of ATP, found its short half-life limited its clinical value [
69]. A subsequent analog, denufosol, showed greater stability and early trials held great promise. A Phase III study (the Transport of Ions to Generate Epithelial Rehydration study (TIGER1)) demonstrated lung function improvement [
70]; however, a second placebo-controlled study (TIGER2) did not duplicate these results and further development for CF was discontinued [
71]. Denufosol was observed to have a relatively short half-life (17 minutes) in a pharmacokinetic sub-study, much shorter than had been predicted from
in vitro and
ex vivo studies [
72], and it may be that study failure was due to simple pharmacokinetics. It is also possible that agents such as denufosol may be capable of changing the rate of lung function decline without necessarily improving lung function, in which case the choice of lung function improvement as the primary efficacy endpoint in the denufosol studies was problematic.
Lancovutide increases intracellular calcium level and activates an alternative chloride channel [
73]. A proof-of-concept clinical study showed promise with increased chloride conductance, as measured by nasal potential difference, when applied topically to nasal epithelium in patients with CF [
74], and a small, single-center clinical trial in 24 patients with CF found that it was safe and benefitted pulmonary function [
75]. However, there has been no further development of this drug in clinical trials.
One of the roles of CFTR is to inhibit sodium absorption and its absence causes excessive sodium (and water) absorption through an epithelial sodium channel [
76]. An alternative approach to CFTR treatment could be to inhibit sodium absorption through the epithelial sodium channel. Aerosolized amiloride (an epithelial sodium channel blocker with a short half-life) not only had no clinical benefit, it showed a trend toward poorer lung function in the treated patients [
77]. There may yet be other channels identified as more relevant in CF lung disease, or agents with a longer half-life may be a better option.
Hydrators
Another proposed approach to restoring airway surface liquid is the direct instillation of salt and water. This has been demonstrated to increase the volume of airway surface liquid in cultured CF airway epithelia [
78] and it has been suggested that inhalation of hypertonic saline can improve mucociliary clearance
in vivo [
79]. In this latter study, the benefit occurred in the first 60 minutes [
79], suggesting either that the increase in mucociliary clearance is a short-lived effect or it is the result of another mechanism, such as transiently increasing the volume of ASL, unbinding secretions from the airway surface and inducing cough. In any case, aerosolized hypertonic saline has demonstrated other clinical benefits. Twice daily inhalation of hypertonic (7% to 8%) saline has been shown to improve ventilation inhomogeneity in patients with CF with 'normal' spirometry [
80]; reduce sputum markers of inflammation [
81]; reduce the risk of pulmonary exacerbation [
36,
82]; and modestly improve pulmonary function [
36,
83]. Dose frequency [
78] and concentration [
84] may affect the magnitude of the inhaled hypertonic saline response. Recently, a large randomized placebo-controlled multicenter 48-week study of inhaled hypertonic saline in children with CF under six years of age failed to demonstrate a treatment-related reduction in the rate of pulmonary exacerbation [
85]. There has yet to be a definitive demonstration that inhalation of lower saline concentrations (commonly prescribed to increase tolerance and adherence) provide clinical benefit [
84].
The challenges of hypertonic saline include poor tolerance because of increased cough and bronchospasm [
36] and the time it takes for aerosolization, adding to the patient's treatment burden. As stated earlier, the benefit of aerosolized hypertonic saline occurs early and could be related to the short time that the drug can affect the phlegm because of rapid absorption. An alternative approach is to deliver an osmotic agent to the airways that could draw water into the airway surface liquid and have a longer presence for which it to be active. Recently, a dry powder formulation of mannitol for inhalation has been developed that presumably shares the inhaled hypertonic saline mechanism(s), and it has been studied in both CF and non-CF bronchiectasis. Similar to the data for hypertonic saline, the improvement in airway clearance also appears to occur in the first 45 minutes, after which the rate of clearance appears to be the same in all doses tested [
86]. Clinical trials of inhaled mannitol resulted in improved lung function and a trend to reduced rates of pulmonary exacerbations; these results seemed to be sustained in an open-label extension of the study [
87]. The drug is currently under review by the FDA. As with hypertonic saline, a substantial minority of patients with CF is intolerant to this therapy, with cough being a frequently observed adverse event [
87].
Xylitol is another sugar with low transepithelial permeability that may function as an osmolar agent similar to mannitol. Early studies have demonstrated safety in mice, healthy volunteers and stable patients with CF when administered over a single day [
88]. Ongoing clinical trials will investigate the safety and efficacy of inhaled xylitol compared with hypertonic saline [
89].
Dornase alfa
Medications have been used to alter the properties of airway phlegm to make it easier to clear from the airways. Both hypertonic saline and mannitol have been demonstrated to alter the properties of sputum and this may be an important component of their clinical benefit [
86,
91]. Recombinant human DNase (dornase alfa) has been developed to cleave high molecular weight DNA released by dead neutrophils that contributes to the tenacity of airway phlegm [
92]. Daily inhalation of aerosolized dornase alfa can reverse early air trapping [
93] and ventilation inhomogeneity [
94]; decrease sputum markers of local inflammation [
92,
95]; reduce pulmonary exacerbation risk [
33,
35]; improve CF pulmonary function [
33,
35]; slow the rate of at which pulmonary function is lost [
96]; and improve survival [
97]. It is generally well-tolerated and has become a mainstay in the recommended treatments to maintain lung health [
98].
Aerosolized antibiotics
As stated earlier, there are several situations in which antibiotics are used to treat CF airways disease. Chronic prophylaxis primarily targets acquisition of
Staphylococcus aureus in infants by use of oral flucloxacillin [
99], but is used only regionally (primarily in the UK and Europe) based upon local experience and tradition, the differential weighting of apparently conflicting study results [
99‐
101] and drug availability. Newly detected
Pseudomonas aeruginosa from throat cultures has been treated with inhaled antipseudomonal antibiotics [
102‐
105] with or without concomitant oral ciprofloxacin and intravenous antipseudomonal antibiotics. Although these interventions are routinely capable of converting >80% of patients to
P. aeruginosa culture negativity [
104,
106‐
109], the ultimate clinical benefit of delaying chronic
P. aeruginosa infection with this approach has not been robustly demonstrated.
Ironically, the potentially most heretical use of antibiotics in CF, the chronic suppression of bacterial opportunists in the airway without their eradication, is the one with the greatest empirical evidence for clinical benefit. Chronic or chronic intermittent administration of the inhaled antipseudomonal antibiotics colistimethate, tobramycin and aztreonam has been associated with improved quality of life [
110,
111], decreased risk of exacerbation [
34,
112], improved pulmonary function [
34,
111], and decreased mortality [
97]. This practice, which has expanded substantially in recent decades [
47], was predated by scheduled, periodic treatment of patients with intravenous antibiotics [
113,
114].
Anti-inflammatory medications
The inflammatory response in the airways of patients with CF is excessive and it is thought that the inflammation overwhelms the natural protective mechanisms of the airway [
115]. It is the excessive and persistent inflammation that is likely to be the main cause of destruction of the airways over time, so it is logical that anti-inflammatory therapy could provide benefit to the progression of CF airways disease.
Chronic administration of oral prednisone has been shown to improve pulmonary function in children with CF [
116] but also to result in significant growth impairment [
117] in a population with preexisting growth challenges. Inhaled corticosteroids may reduce the potential for adverse effects, but the evidence for the benefit of chronic inhalation of corticosteroids is conflicting [
98,
118‐
120]. There has never been a randomized controlled trial describing the treatment benefit of inhaled corticosteroids, although a controlled study has demonstrated that withdrawal of the inhaled corticosteroid fluticasone was not associated with an increased rate of exacerbation or reduced pulmonary function during a six-month post withdrawal period [
118]. However, two retrospective CF registry analyses have independently shown an association between chronic inhaled corticosteroid use and a reduced rate of lung function decline over a period of years [
119,
120], again suggesting that short-term measures of respiratory health may not be perfect surrogates for longer-term disease progression. Current US chronic respiratory therapy guidelines recommend against the use of inhaled corticosteroids in patients without asthma [
98], although their use remains extremely common [
47], perhaps in part because of the very low treatment burden associated with the administration of drug via a metered-dose inhaler.
As an alternative, nonsteroidal anti-inflammatory drugs have been studied as a treatment of CF lung disease. Ibuprofen, when taken in high doses, inhibits the migration, adherence and aggregation of neutrophils [
121‐
123]. Despite prospective and retrospective demonstration that chronic administration of high dose ibuprofen reduces the rates of pulmonary function decline [
124‐
126], less than 10% of eligible patients in the US receive this therapy [
1,
47] due to concerns for rare, but very serious, gastric bleeding associated with the treatment [
124].
Macrolide antibiotics are currently recommended as a chronic therapy for patients with CF to improve lung function and reduce exacerbations [
98], despite some degree of uncertainty as to the exact mechanism(s) by which macrolides exert their clinical effect. Although azithromycin, the macrolide most commonly prescribed to patients with CF, is marketed as an antibiotic, there is substantial evidence that a reduction in airway inflammation plays a key role in its efficacy in CF. The clinical evidence of a macrolide-derived anti-inflammatory effect includes a decrease in the number of neutrophils present at the site of infection [
127‐
130] and a reduction in pro-inflammatory cytokines that recruit more neutrophils [
131,
132]. EM703, a macrolide variant with essentially no antimicrobial activity [
133], retains strong immunomodulatory properties and has been shown to protect against chemically-induced pulmonary fibrosis in an animal model [
134]. Generally, macrolides such as azithromycin are not considered to be effective against
Pseudomonas using traditional
in vitro susceptibility testing for CF bacterial isolates, although reports of clinical benefit have been derived from large studies in persons with CF and chronic
P. aeruginosa infection [
135,
136]. However,
in vitro studies have suggested that the clinical efficacy of azithromycin may result directly from a cidal activity against
Pseudomonas [
137,
138] or indirectly by inhibition of bacterial biofilm production [
139,
140]. Patients with CF receiving chronic azithromycin have been shown to culture strains of
S. aureus and
Haemophilus influenzae with progressively reduced macrolide sensitivities over time, indicative of an antibiotic effect, although not one directed against
Pseudomonas [
141]. The question of whether the macrolide benefit in CF results from either direct suppression of inflammation or from an antimicrobial effect, or both, is of more than academic importance. Presumably, individuals are less likely to become refractory to an anti-inflammatory effect with chronic exposure, while the same may not be true for chronic antibiotic exposure.
As stated earlier, the neutrophil-dominated inflammation in the airways overwhelms the natural protection, notably the neutrophil elastase alpha1-antitrypsin (A1AT). When given in aerosol form to 12 patients with CF, A1AT suppressed neutrophil elastase in the respiratory ASL and reversed the inhibitory effect of CF ASL on
Pseudomonas-killing by neutrophils [
142]. Early studies of A1AT treatment have demonstrated a decrease in inflammatory parameters after treatment [
142,
143]. The challenge to this therapy is the ability to deliver an effective dose to the airways. New technologies of aerosol devices may make this therapy more viable.
Another observation in CF airways disease is that there is a reduction in glutathione, an important component of airway defense, in the lower airways as measured in bronchoalveolar lavage fluid [
144]. It has been suggested that replacement of glutathione directly, or indirectly be replacing sulfhydryl groups through administration of N-acetyl cysteine (NAC) might reduce the inflammatory response. A pilot study of inhaled glutathione in 19 patients with CF suggested a trend towards improved inflammatory outcomes [
145]. Early trials suggested that high dose NAC might also reduce the inflammatory state, but a single-center study failed to demonstrate a change in clinical or inflammatory parameters in the bronchoalveolar lavage fluid of patients [
146]. Nonetheless, extracellular glutathione in induced sputum tended to increase on high-dose NAC, suggesting there was an effect on increasing available glutathione. Whether enhancing airway glutathione levels by either approach will improve CF lung health remains to be demonstrated.
Lung transplantation
For those patients who progress to an advanced severity, lung transplantation may be an option. In carefully selected patients, lung transplantation has demonstrated great success with a one-year survival of approximately 90%, but the five-year survival is only 50%, most likely because of the development of chronic rejection as bronchiolitis obliterans [
147]. The etiology of chronic rejection remains debated but a prime strategy of treating it, or trying to prevent it, is chronic administration of anti-rejection medications, such as cyclosporine A and tacrolimus [
148]. A principal adverse event associated with long-term immunosuppression is chronic renal insufficiency, a complication that has led to the study of inhaled cyclosporine A (originally studied as a rescue medication for acute transplant rejection [
149]) as a topical alternative for long-term immunosuppression to reduce systemic exposure. A small single-center randomized controlled clinical study suggested that treatment of lung transplant recipients with inhaled cyclosporine A beginning shortly after transplant reduced chronic rejection and improved survival while not increasing the risk of infection [
149]. A large multicenter controlled clinical trial of inhaled cyclosporine (NCT00755781) has apparently completed enrollment, but no results from this Phase III study have been released.